Centre of Excellence
Specialties
Treatments and Procedures
Hyderabad
Raipur
Bhubaneswar
Visakhapatnam
Nagpur
Indore
Chh. Sambhajinagar
Clinics & Medical Centers
Online Lab Reports
Book an Appointment
Consult Super-Specialist Doctors at CARE Hospitals
Rituximab emerged as a groundbreaking monoclonal antibody medication. Doctors use it to treat several autoimmune diseases and cancer types. The drug has proven its worth in managing conditions like non-Hodgkin lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis. Doctors found new ways to help patients with this treatment beyond its original purpose. The drug now helps treat rare conditions like immune thrombocytopenic purpura and Rasmussen encephalitis. This article explains its mechanisms in the body, proper administration methods, side effects, and key precautions.
Rituximab is a specialised anti-CD20 monoclonal antibody. The protein targets CD20 markers on B cells, which makes it effective for B cell-related diseases. Doctors give it in injection or infusion form.
Rituximab helps to treat many cancerous and non-cancerous conditions. These are:
Rituximab comes as an infusion only, not a tablet. Doctors must administer this medicine in a clinical setting. Patients receive acetaminophen and antihistamines before each infusion to minimise reactions. Each treatment session lasts several hours, and the initial treatment usually involves two infusions spaced two weeks apart.
Most patients (80-90%) experience infusion reactions within 30-120 minutes after treatment begins. Common side effects are:
Lymphopenia, serious skin & mouth infections, and heart problems are other serious side effects.
Rituximab functions as a monoclonal antibody that targets a specific protein called CD20 found on B cells. The drug works through multiple mechanisms after attaching to these cells:
You should exercise caution because rituximab interacts with many medicines. Common interactions are:
Each condition requires different dosing:
Doctors must administer rituximab in a medical setting. Patients receive appropriate premedication to reduce infusion reactions.
Rituximab is a monoclonal antibody that targets B cells with precision and helps patients with lymphomas, leukaemia and autoimmune disorders. Medical staff can give rituximab through an infusion. Patients get their treatment over several hours while the medical team watches for any reactions. Each condition needs its own dosage and most treatments follow a schedule that spans multiple weeks.
These precautions aside, rituximab proves its worth as a crucial medicine worldwide. More doctors use it for off-label treatments now than ever before, which shows how much they value this option. Rituximab often works when other treatments don't, giving hope to patients with tough diagnoses.
Rituximab comes with several serious risks. Infusion reactions affect 80-90% of patients. These reactions usually happen within 30-120 minutes after the first infusion. The most important risks include:
You won't see results right away. Rheumatoid arthritis patients usually notice improvements between 8-16 weeks after treatment begins. Cancer patients with non-Hodgkin's lymphoma typically respond around 50 days (about 7 weeks). Kidney disease patients often see changes within 4-6 weeks.
Contact your doctor's office right away. Your symptoms might flare up if you skip doses. Your healthcare team will work to reschedule your infusion quickly.
Overdose patients face higher risks of severe reactions that can be fatal during infusion. Medical staff will provide symptomatic and supportive care.
Stay away from:
Rituximab isn't safe for people with:
Rituximab differs from regular medicines since patients can't take it themselves. Doctors must administer this medication in a hospital or clinic setting. The treatment consists of an intravenous infusion that lasts four to six hours. Doctors create specific infusion schedules based on each patient's condition.
Each condition needs a different treatment duration. Rheumatoid arthritis patients usually receive two infusions two weeks apart. Patients with vasculitis might need four weekly infusions. Maintenance treatments typically happen every six months after that.
Your doctor will decide the right time to end your treatment. Maintenance treatments can last 24-48 months. Doctors might stop treatment for pemphigus patients who maintain complete remission with low antibody levels for at least one year.
Rituximab doesn't work as a daily medication. The treatment follows specific schedules with weeks or months between doses. This spacing allows proper B-cell depletion while reducing side effects.
The gap between doses matters more than the actual time of day. Afternoon appointments might suit patients on blood pressure medications better, as doctors often recommend pausing these medications 12 hours before treatment.
After your infusion, avoid: